Solid tumors are numerous cancers that can occur in many parts of the body, including brain cancer, ovarian cancer, breast cancer, colon cancer, and other tissue cancers. Cancer is the product of a microevolutionary process in which proto-oncogenes and tumor suppressors have unique forms of molecular alterations that vary with the individual, organ, and tissue. These mutations will affect cellular signaling in complex ways, leading to cancer development and progression.
CD Genomics provides solid tumor analysis services relying on next generation sequencing (NGS) technology. Amplification-based and hybridization capture-based targeted sequencing of hundreds of solid tumor-associated genes, as well as whole exome and genome sequencing, resolve cancer genomes and tissue-specific analytical profiles. Our rapid and reliable NGS workflow provides quality control, data analysis, and variant interpretation pipelines to evaluate millions of bases in the genome, revealing cancer driver genes, cancer signaling pathways, biomarkers, drug targets, resistance, and genetic susceptibility.
Specimen: Extracted genomics DNA and FFPE samples
Sample purity: 1.8 ≤ OD260/280 ≤ 2.0, OD260/230 ≥ 2.0
Recommended amount: > 2 μg, > 20 ng / μL
Collection: DNA samples are stored in TE buffer or equivalent. FFPE samples (recommended cryopreservation). Please make sure that the DNA is not degraded.